COMMUNIQUÉS West-GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/05/2019
CAMBRIDGE, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in [...]
IntelGenx Announces Issuance of Second U.S. Patent for Topical Oral Film Technology
01/05/2019
SAINT LAURENT, Quebec, May 01, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that the United States Patent and Trademark Office [...]
Phoenix Life Announces $40 Million Capital Raise in Conjunction with TABOR Family Office Conference
01/05/2019
DENVER, CO, May 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - Phoenix Life Sciences International Limited (OTC: PLSI) (“Phoenix Life” or the “Company”), an adaptive healthcare solutions company, today announced that [...]
Tauriga Sciences, Inc. Enters into Distribution Agreement Focused on Tauri-Gum Sales Throughout Northeast Region of USA and Asia
01/05/2019
NEW YORK, NY, May 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Tauriga Sciences, Inc. (OTCQB: TAUG ) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and [...]
Adaptimmune to Provide Clinical and Business Update on Monday May 6th, 2019
01/05/2019
PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will provide a clinical and business update before [...]
Xeris Pharmaceuticals Announces Results From a Phase 1 Study of Its Novel Formulation of Diazepam
01/05/2019
Favorable pharmacokinetic, safety, and tolerability results support continued development of Xeris’ diazepam Phase 2 study to be initiated in 2H2019 CHICAGO, May 01, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc [...]
Stryker declares a $0.52 per share quarterly dividend
01/05/2019
Kalamazoo, Michigan, May 01, 2019 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.52 per share payable on July 31, 2019 to shareholders of record at [...]
Abeona Therapeutics présente des données précliniques démontrant un large potentiel thérapeutique de la thérapie génique AIM™ dans les maladies rétiniennes lors de l'assemblée générale annuelle de l'Association for Research in Vision and Ophthalmology
01/05/2019
NEW YORK et CLEVELAND, 01 mai 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq : ABEO), chef de file totalement intégré dans la thérapie génique et cellulaire, a annoncé aujourd'hui que l'administration [...]
Verrica Pharmaceuticals Announces Participation in Upcoming Investor Conferences
01/05/2019
WEST CHESTER, Pa., May 01, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that [...]
Nephros to Report First Quarter 2019 Financial Results on May 8, 2019
01/05/2019
SOUTH ORANGE, NJ, May 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, [...]
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results
01/05/2019
Enrollment complete in Magnolia and Amaryllis studies RADNOR, Pa., May 01, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative [...]
Checkpoint Therapeutics Announces Positive Interim Clinical Results of Anti-PD-L1 Antibody Cosibelimab
01/05/2019
>40% objective response rates observed in first-line non-small cell lung cancer and cutaneous squamous cell carcinoma Well-tolerated safety profile Enrollment ongoing in expansion cohorts intended to support [...]
Translate Bio Announces $47.5 Million Private Placement
01/05/2019
LEXINGTON, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat [...]
Otonomy to Participate in SunTrust Robinson Humphrey Life Sciences Summit
01/05/2019
SAN DIEGO, May 01, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the company will host [...]
Strongbridge Biopharma plc Reports First Quarter 2019 Financial Results and Provides Corporate Update
01/05/2019
~ Following Type C Meeting with the U.S. Food & Drug Administration (FDA), Strongbridge Plans to Submit its New Drug Application (NDA) for RECORLEV™ (levoketoconazole) in the Third Quarter of 2020; Submission to [...]
Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases
01/05/2019
Data demonstrate that pre-symptomatic infants with SMA treated with SPINRAZA ® (nusinersen) over three years achieved motor milestones that are more consistent with normal childhood development Late-breaking data expand [...]
CURE Pharmaceutical Extends Closing Of Privately-Held Chemistry Holdings Inc. Acquisition to May 13
01/05/2019
OXNARD, Calif., May 01, 2019 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR) (“CURE”), an innovative drug delivery and development company, today announced that it has extended the close of the previously announced [...]
Apollomics, Inc. Appoints Fabio M. Benedetti, M.D. as Chief Medical Officer
01/05/2019
FOSTER CITY, Calif. and HANGZHOU, China, May 01, 2019 (GLOBE NEWSWIRE) -- Apollomics, Inc. (the “Company”), an innovative biopharmaceutical company committed to the discovery and development of oncology combination [...]
Myriad Genetics to Present at Two Upcoming Healthcare Conferences
01/05/2019
SALT LAKE CITY, May 01, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that it will be presenting at two upcoming healthcare [...]

Pages